What's new
Blood Biomarkers can widen access to dementia diagnosis in less well resourced settings
16 February 2026
The World Alzheimer Report 2019 said there will be around 152 million people with dementia globally by 2050, with the greatest increase in lower and middle-income countries, where populations continue to grow. Blood biomarkers are highly accessible for use in diagnosis, and there is very strong potential for them to be valuable in low- and middle-income countries (LMICs) where they can be scalable and extend accurate diagnosis.
'Embracing Complexity' - DPUK 2025 Annual Report published
2 February 2026
'Embracing Complexity' - the title of our 2025 Annual Report - has its origin in a recurring theme across its pages. It is a recurrent issue in a range of articles embracing: emerging data needs, AI risks and opportunities, relationships with industry, open knowledge architecture for better interoperability, the search for an efficient and effective way to diagnose dementias in the NHS, international collaboration.
Latest blood biomarker study for Alzheimer’s joins the drive towards easy-to-access diagnosis
21 January 2026
The latest biomarker study to translate promising studies into real-world validated tests to diagnose Alzheimer’s disease was announced this week. It aims to help identify blood tests that could help predict the presence of amyloid plaques or tau tangles in the brain, which are the hallmarks of Alzheimer’s disease.
Vascular dementia clinical trial, LACI-Cog, seeks public views of plans
19 January 2026
A DPUK study testing new treatments for vascular cognitive impairment and vascular dementia, is looking for people to complete a survey about the study and their approach to the work.
How is Dementias Platform UK enhancing research into dementia?
Watch this introductory video about Dementias Platform UK (DPUK) and how it is bringing together the best scientific minds and global leaders in the pharmaceutical industry to find new ways of detecting, treating and preventing dementia.
Get the DPUK newsletter
Sign up to subscribe to the DPUK newsletter.
Keep up to date with all that's going on at Dementias Platform UK. There are around 4 newsletters a year, which include news about developments in our infrastructure services, studies, partnerships and collaborations.
Social Media
We're currently active on LinkedIn, X (Twitter) and BlueSky where we post about every aspect of DPUK. Most of our news is shared on these channels first including jobs, new studies, programme's milestones, information on training, seminars and conferences.
Science feature
Potential use for blood biomarkers in dementia diagnosis where medical resources are limited
Blood biomarkers are highly accessible for use in diagnosis, and there is very strong potential for them to be valuable in low- and middle-income countries (LMICs) where they can be scalable and extend accurate diagnosis.
The DPUK Data Portal gives researchers rapid, secure access to multimodal datasets and millions of health research records.
Our Trials Delivery Framework matches public volunteers to the right dementia studies and has over 80 clinical sites across the UK.
DPUK's Experimental Medicine Incubator accelerates and de-risks the development of new treatments for dementia.
Work with us
Would you like to increase the international visibility of your data? Try our Data Portal.
Do you need well-characterised volunteers for your early-phase trial? Use our Trials Delivery Framework.
Is there a mechanism you would like to investigate? Explore our Experimental Medicine Incubator.